KAMES CAPITAL plc acquired a new position in Bristol-Myers Squibb Co (NYSE:BMY) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 3,693 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.
A number of other hedge funds also recently bought and sold shares of BMY. CSat Investment Advisory L.P. bought a new position in Bristol-Myers Squibb in the 2nd quarter worth approximately $113,000. Landaas & Co. WI ADV bought a new position in Bristol-Myers Squibb in the 2nd quarter worth approximately $131,000. Mount Yale Investment Advisors LLC bought a new position in Bristol-Myers Squibb in the 1st quarter worth approximately $179,000. LFA Lugano Financial Advisors SA raised its position in Bristol-Myers Squibb by 85.8% in the 3rd quarter. LFA Lugano Financial Advisors SA now owns 3,207 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 1,481 shares during the last quarter. Finally, Pure Financial Advisors Inc. bought a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $201,000. Hedge funds and other institutional investors own 72.28% of the company’s stock.
BMY has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 price objective for the company in a research report on Friday, October 5th. Atlantic Securities upgraded shares of Bristol-Myers Squibb from an “underweight” rating to a “neutral” rating and set a $57.00 price objective for the company in a research report on Wednesday, August 8th. Jefferies Financial Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Sunday, July 15th. BMO Capital Markets reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a report on Sunday, July 22nd. Finally, Credit Suisse Group reaffirmed a “hold” rating and set a $61.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, September 12th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and seven have issued a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $62.95.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The firm had revenue of $5.70 billion during the quarter, compared to analyst estimates of $5.48 billion. During the same quarter in the previous year, the business earned $0.74 EPS. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. Equities analysts expect that Bristol-Myers Squibb Co will post 3.62 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, November 1st. Stockholders of record on Friday, October 5th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.78%. The ex-dividend date is Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Further Reading: Book Value Per Share in Stock Trading
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.